Cargando…
Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease
Simufilam is a novel oral drug candidate in Phase 3 clinical trials for Alzheimer’s disease (AD) dementia. This small molecule binds an altered form of filamin A (FLNA) that occurs in AD. This drug action disrupts FLNA’s aberrant linkage to the α7 nicotinic acetylcholine receptor (α7nAChR), thereby...
Autores principales: | Wang, Hoau-Yan, Cecon, Erika, Dam, Julie, Pei, Zhe, Jockers, Ralf, Burns, Lindsay H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531384/ https://www.ncbi.nlm.nih.gov/pubmed/37762230 http://dx.doi.org/10.3390/ijms241813927 |
Ejemplares similares
-
Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes
por: Wang, Hoau-Yan, et al.
Publicado: (2023) -
Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017) -
Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET
por: Cecon, Erika, et al.
Publicado: (2021) -
Naloxone's Pentapeptide Binding Site on Filamin A Blocks Mu Opioid Receptor–Gs Coupling and CREB Activation of Acute Morphine
por: Wang, Hoau-Yan, et al.
Publicado: (2009) -
High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence
por: Wang, Hoau-Yan, et al.
Publicado: (2008)